About this trial
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.
Eligibility criteria
Qualifiers
None
Disqualifiers
Has previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC)
Able to undergo protocol therapy, including necessary surgery
Confirmation that epidermal growth factor receptor (EGFR) -directed therapy is not indicated as primary therapy
Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 as assessed within 10 days before initiation of study intervention.
Trial design
Treatments tested in this trial
- Pembrolizumab (neoadjuvant)
- Cisplatin
- Gemcitabine
- Pemetrexed
- Sacituzumab tirumotecan
- H1 receptor antagonist
- H2 receptor antagonist
- Acetaminophen (or equivalent)
- Dexamethasone (or equivalent)
- Carboplatin
- Pembrolizumab (adjuvant)
- Paclitaxel
- Steroid mouthwash (dexamethasone or equivalent)